Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.71 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylbutazone SCHEMBL3632 | 0.88 | RAB9A (0.82) | CYP3A4ALDH1A1CYP2C9CYP2C19MAPT | |
| Phenylbutazone SCHEMBL8005041 | 0.88 | RAB9A (0.82) | CYP3A4ALDH1A1CYP2C9CYP2C19MAPT | |
| Phenylbutazone SCHEMBL2122724 | 0.87 | RAB9A (0.80) | CYP3A4ALDH1A1CYP2C9CYP2C19MAPT | |
| Phenylbutazone SCHEMBL21694456 | 0.87 | RAB9A (0.80) | CYP3A4ALDH1A1CYP2C9CYP2C19MAPT | |
| Phenylbutazone SCHEMBL2874252 | 0.87 | RAB9A (0.80) | CYP3A4ALDH1A1CYP2C9CYP2C19MAPT | |
| Phenylbutazone SCHEMBL10913190 | 0.87 | RAB9A (0.80) | CYP3A4ALDH1A1CYP2C9CYP2C19MAPT | |
| Phenylbutazone SCHEMBL7715162 | 0.87 | RAB9A (0.80) | CYP3A4ALDH1A1CYP2C9CYP2C19MAPT | |
| Phenylbutazone SCHEMBL7460714 | 0.86 | ALDH1A1 (0.70) | CYP3A4ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL21694458 | 0.84 | RAB9A (0.68) | CYP3A4ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL11814216 | 0.83 | ALDH1A1 (0.67) | CYP3A4ALDH1A1CYP2C9CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | PREMIER RESEARCH INTERNATIONAL, LLC | 2023-11-14 | — | — | US | disclosed |
| US-11685739-B2 | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
| US-11685739-B2 | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | TECHFIELDS PHARMA CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
| US-11084813-B2 | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | TECHFIELDS PHARMA CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-20190152991-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | TECHFIELDS PHARMA CO LTD (CN) | 2019-05-23 | — | — | US | disclosed |
| US-10233198-B2 | Pro-drugs of NSAIAs with very high skin and membranes penetration rates and their new medicinal uses | TECHFIELDS PHARMA CO., LTD. (CN) | 2019-03-19 | — | — | US | disclosed |
| US-20170334908-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | PREMIER RESEARCH INTERNATIONAL, LLC | 2017-11-23 | — | — | US | disclosed |
| US-20170334908-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | PREMIER RESEARCH INTERNATIONAL, LLC | 2017-11-23 | — | — | US | disclosed |
| US-20160002157-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | PREMIER RESEARCH INTERNATIONAL, LLC | 2016-01-07 | — | — | US | disclosed |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2015-03-12 | — | — | US | disclosed |
| US-20100172960-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | PREMIER RESEARCH INTERNATIONAL, LLC | 2010-07-08 | — | — | US | disclosed |
| US-20080287390-A1 | Pyrazolidinol compounds | A-VIRAL AS (NO) | 2008-11-20 | — | — | US | disclosed |
| US-20070037772-A1 | Pyrazolidinol compounds | A-VIRAL AS (NO) | 2007-02-15 | — | — | US | disclosed |
| EP-1194409-B1 | PYRAZOLIDINOL COMPOUNDS | VIRAL ASA A (NO) | 2006-02-01 | — | — | EP | disclosed |
| US-6852749-B1 | Pyrazolidinol compounds | A-VIRAL AS (NO) | 2005-02-08 | — | — | US | disclosed |
| US-20040152751-A1 | Pyrazolidinol compounds | TJOTTA ENOK (NO) | 2004-08-05 | — | — | US | disclosed |
| EP-1194409-A1 | PYRAZOLIDINOL COMPOUNDS | A-Viral AS (NO) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001000585-A1 | PYRAZOLIDINOL COMPOUNDS | A-VIRAL AS (NO) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | CYP3A4 49/4885ALDH1A1 1724/4885CYP2C9 42/4885 |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | CPA3, PAH, HCAR2 | CYP3A4 23/4885ALDH1A1 2282/4885CYP2C9 29/4885 |
| US-20080287390-A1 | Pyrazolidinol compounds | NOX5, TPMT, ICOS | CYP3A4 184/4885ALDH1A1 587/4885CYP2C9 230/4885 |
| US-20170334908-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | ABCB1, PARK7, SLC5A7 | CYP3A4 113/4885ALDH1A1 1689/4885CYP2C9 98/4885 |
| US-20190152991-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | MYLK2, SLC2A1, SLC2A2 | CYP3A4 3744/4885ALDH1A1 4095/4885CYP2C9 3949/4885 |
| US-20070037772-A1 | Pyrazolidinol compounds | NOX5, TPMT, ICOS | CYP3A4 184/4885ALDH1A1 587/4885CYP2C9 230/4885 |
| US-10233198-B2 | Pro-drugs of NSAIAs with very high skin and membranes penetration rates and their new medicinal uses | MYLK2, ALPI, SLC2A2 | CYP3A4 3836/4885ALDH1A1 3863/4885CYP2C9 3975/4885 |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | CYP3A4 49/4885ALDH1A1 1724/4885CYP2C9 42/4885 |
| US-20040152751-A1 | Pyrazolidinol compounds | NOX5, TPMT, ICOS | CYP3A4 184/4885ALDH1A1 587/4885CYP2C9 230/4885 |
| US-20100172960-A1 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES | MYLK2, ALPI, SLC2A2 | CYP3A4 3836/4885ALDH1A1 3863/4885CYP2C9 3975/4885 |
| US-11084813-B2 | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | ABCB1, PARK7, ABCG2 | CYP3A4 75/4885ALDH1A1 1488/4885CYP2C9 59/4885 |
| US-20160002157-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | ABCB1, PARK7, SLC5A7 | CYP3A4 113/4885ALDH1A1 1689/4885CYP2C9 98/4885 |
| US-11685739-B2 | High penetration drugs and their compositions thereof for treatment of Parkinson diseases | ABCB1, PARK7, ABCG2 | CYP3A4 75/4885ALDH1A1 1488/4885CYP2C9 59/4885 |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | HRH4, HCAR2, PAH | CYP3A4 49/4885ALDH1A1 1724/4885CYP2C9 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.